2:28 PM
 | 
May 24, 2019
 |  BC Extra  |  Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine
Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted the Gilead Sciences Inc. (NASDAQ:GILD) unit an exclusive license to two programs from Alpine's transmembrane immunomodulatory protein technology, which Kite was to use to develop CAR and TCR product candidates. Gilead declined to disclose details (see...

Read the full 328 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >